



Patent Application  
Attorney Docket No. PC10866A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Chen, et al.

APPLICATION NO.: 09/836,035 : Examiner: Huang, E.M.

FILING DATE: 04/17/2001 : Group Art Unit: 1625

TITLE: Sodium-Hydrogen Exchanger Type 1 Inhibitor

Hon. Commissioner for Patents  
Box CPA  
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to § 37 C.F.R. 1.97(b)(3); and 1.98, Applicants wish to draw the Examiner's attention to PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the Continued Prosecution Application of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


The Examiner is respectfully requested to indicate his or her consideration of the foregoing item by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the same to the undersigned. It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Authorization is hereby provided to charge any fees required, or credit to any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

A prompt and favorable response is earnestly solicited.

Date: Sept. 27, 2002

Respectfully submitted,

  
Martha G. Munchhof  
Attorney for Applicant(s)  
Reg. No. 47,811

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4288

OCT 02 2002

RECEIVED  
TECH CENTER 1600/2900